Economic Atlas
Companies/Travere Therapeutics, Inc.
Company profile

Travere Therapeutics, Inc.

NASDAQ: TVTX · Healthcare · Biotechnology
PublicHQ San Diego, CA · San DiegoCIK 0001438533Reports USD
#216 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
74B
Revenue TTM
$536.2M
Rev growth YoY (TTM)
+96.0%
Net income (FY)
-$25.5M
Employees
497
as of 2026-08-07
Market cap
$5.8B
as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$490.7M$490.7M2025
Net income-$25.5M-$25.5M2025
Operating income-$62.8M-$62.8M2025
Total assets$605.2M$605.2M2025
Liabilities$490.4M$490.4M2025
Equity$114.8M$114.8M2025

Revenue trend

FY2023 – FY2025 · USD
FY23
FY22
FY23
FY23
FY23
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Product84%
License16%
By geography

Not disclosed.

The read

What is Travere Therapeutics, Inc.’s revenue?

Travere Therapeutics, Inc. booked $490.7M in FY2025 revenue, growing 110% year over year — faster than most Healthcare companies we track, at a -5.2% net margin.

Peers · Healthcare
BridgeBio Pharma, Inc.53DAscend Wellness Holdings, Inc.53DInyx, Inc.——Phreesia, Inc.68BAyr Wellness Inc.——Accuray Incorporated68B
Neighbors
San Diego →
QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60CSempra$12.4B64CDexCom, Inc.$4.7B87AResMed Inc.$5.1B88AIllumina, Inc.$4.3B84B+
Key facts
CEOEric Dube
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: TVTX
Employees497
IPO date2012-11-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.